Department of Medical, Oral and Biotechnological Sciences, "G. d'Annunzio" University, Chieti, Italy.
Unit of General Surgery, "Renzetti" Hospital, Lanciano, Italy.
ANZ J Surg. 2022 Jan;92(1-2):132-139. doi: 10.1111/ans.17264. Epub 2021 Oct 12.
To examine the outcome of patients treated with complete mesocolic excision (CME) with central vascular ligation (CVL) after conventional and laparoscopic surgery.
We retrospectively evaluated stage I-IV colon adenocarcinoma patients treated by the same surgeon (L.M.) from 2013 to 2018. Postoperative complications, recurrences and survival are assessed.
Fifty-one patients (M/F: 24/27) underwent laparoscopic right hemicolectomy with CME (L-CME) or open CME (O-CME) plus CVL. Tumour location was the caecum in 39.2% of cases, the transverse in 23.5%, the hepatic colonic flexure in 21.5%, and the ascending colon in 15.6%. Twenty-four patients underwent L-CME while 27 underwent O-CME. More than 15 harvested lymphnodes are reported in 74.1% of O-CME patients and in 66.7% of L-CME patients (p = 0.562). Postoperative complications occurred in 7 O-CME and 5 L-CME patients, respectively (p = 0.669). Three-year overall survival, including stage IV, was of 75% versus 77.8% for L-CME and O-CME patients, respectively, while for stage I-III, was of 88.9% vs. 80% in L-CME and O-CME, respectively (p = 0.440). The median follow-up was of 2.43 years.
CME with CVL is a meticulous, complex but feasible technique. In our experience, oncological results in terms of recurrences and overall survival, after conventional and laparoscopic CME plus CVL, are comparable. Patients with stage I-III colon adenocarcinoma have a better prognostic trend especially when more than 15 lymphnodes are removed. The respect of oncological radicality and the correct indication to minimally invasive surgery are the undiscussed key outcome variables.
研究接受完整结肠系膜切除术(CME)联合中央血管结扎(CVL)治疗的患者在传统手术和腹腔镜手术后的结局。
我们回顾性评估了 2013 年至 2018 年期间由同一位外科医生(L.M.)治疗的 I-IV 期结肠腺癌患者。评估术后并发症、复发和生存情况。
51 例患者(男/女:24/27)接受了腹腔镜右半结肠切除术联合 CME(L-CME)或开放 CME(O-CME)联合 CVL。肿瘤位置位于盲肠的占 39.2%,横结肠的占 23.5%,肝结肠曲的占 21.5%,升结肠的占 15.6%。24 例患者行 L-CME,27 例患者行 O-CME。O-CME 患者中超过 15 个淋巴结被切除的比例为 74.1%,L-CME 患者为 66.7%(p=0.562)。O-CME 患者中有 7 例和 L-CME 患者中有 5 例发生术后并发症(p=0.669)。包括 IV 期在内的 3 年总生存率,L-CME 和 O-CME 患者分别为 75%和 77.8%,而 I-III 期患者分别为 88.9%和 80%(p=0.440)。中位随访时间为 2.43 年。
CME 联合 CVL 是一种精细、复杂但可行的技术。根据我们的经验,在传统手术和腹腔镜 CME 联合 CVL 后,在复发和总体生存方面的肿瘤学结果是可比的。对于 I-III 期结肠腺癌患者,特别是在切除超过 15 个淋巴结时,预后趋势更好。尊重肿瘤学的根治性和对微创手术的正确适应证是不可忽视的关键预后变量。